Another Paper Supports Anavex's SIGMAR1 Platform Just a day before Anavex published release with reference to a paper looking into Alzheimer's patients brain geograghy of mitochodrial dysfunction, synaptic density, oxidative stress and their impact on brain volume. All this was done in vivo that is on living AD patients as novel radiograghic markers to measure … Continue reading SIGMAR1 As Cell Stress Indicator In Alzheimer’s Points To Great Results In Phase 2b/3 For Blarcamesine. $AVXL

The Addage That Prevention Is Better Than Cure In Alzheimer's and Dementia The searche for the "cure" has been disapointing. The protocols for recruitment in clinical tests for most of the players in the game have gone from including Moderate Dementia patients to only going after those having scores on above 20 MMSE or Mild … Continue reading The Real McCoy In Pursuit of Alzheimer’s Cure Is Prevention Of Deterioration, Not A “Cure”. Anavex Sciences Narrative Goes This Way. Blarcamesine $AVXL

Going Back To The Baseline These are my first impressions from looking into the simufilam data released few days ago from the 12 months open label trial. The initial data for the 6 and 9 months included only 50 subjects. The current data includes 100 subjects. When the 9 months data was released a following … Continue reading First Impressions From Simufilam Data on Open Label 12 Month Trial. $SAVA Simufilam Blarcamesine $AVXL